Shopping Cart 0
Cart Subtotal
USD 0

Amarantus Bioscience Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The company's therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing assay. Amarantus provides DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company also offers phenoguard protein discovery engine platform. It provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis, among others. The company develops diagnostics and therapeutics pipeline products for diseases associated with neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.

Amarantus Bioscience Holdings Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13

Venture Financing 15

Amarantus Therapeutics Raises USD 1.3 Million In Venture Financing 15

Partnerships 16

Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16

Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17

Licensing Agreements 18

Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18

Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 19

Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 20

Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 21

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 23

Equity Offering 24

Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 24

Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 25

Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 26

Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 27

Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 29

Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 30

Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 31

Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 33

Debt Offering 34

Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 34

Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 35

Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For USD 1.6 Million 36

Acquisition 38

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 38

Amarantus Bioscience Holdings Inc-Key Competitors 39

Amarantus Bioscience Holdings Inc-Key Employees 40

Amarantus Bioscience Holdings Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Strategy And Business Planning 42

Apr 17, 2017: Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology 42

Corporate Communications 44

Apr 23, 2018: Cutanogen Names Richard Kagan As Chief Medical Advisor 44

Apr 23, 2018: Cutanogen Names Richard Kagan As Chief Medical Advisor 45

Apr 05, 2018: Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor 46

Clinical Trials 47

Apr 30, 2018: Elto PharmaAppoints Paula Trzepacz, MD as Chief Medical Advisor 47

Other Significant Developments 48

Jul 20, 2018: Amarantus provides corporate update 48

May 11, 2018: Amarantus Provides Business Overview 50

Dec 01, 2017: Amarantus Provides Comprehensive Corporate Update 53

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13

Amarantus Therapeutics Raises USD 1.3 Million In Venture Financing 15

Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16

Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17

Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18

Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 19

Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 20

Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 21

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 23

Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 24

Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 25

Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 26

Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 27

Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 29

Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 30

Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 31

Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 33

Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 34

Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 35

Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For USD 1.6 Million 36

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 38

Amarantus Bioscience Holdings Inc, Key Competitors 39

Amarantus Bioscience Holdings Inc, Key Employees 40

Amarantus Bioscience Holdings Inc, Other Locations 41

Amarantus Bioscience Holdings Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amarantus Bioscience Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The company's therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing assay. Amarantus provides DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company also offers phenoguard protein discovery engine platform. It provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis, among others. The company develops diagnostics and therapeutics pipeline products for diseases associated with neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.

Amarantus Bioscience Holdings Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13

Venture Financing 15

Amarantus Therapeutics Raises USD 1.3 Million In Venture Financing 15

Partnerships 16

Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16

Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17

Licensing Agreements 18

Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18

Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 19

Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 20

Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 21

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 23

Equity Offering 24

Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 24

Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 25

Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 26

Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 27

Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 29

Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 30

Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 31

Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 33

Debt Offering 34

Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 34

Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 35

Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For USD 1.6 Million 36

Acquisition 38

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 38

Amarantus Bioscience Holdings Inc-Key Competitors 39

Amarantus Bioscience Holdings Inc-Key Employees 40

Amarantus Bioscience Holdings Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Strategy And Business Planning 42

Apr 17, 2017: Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology 42

Corporate Communications 44

Apr 23, 2018: Cutanogen Names Richard Kagan As Chief Medical Advisor 44

Apr 23, 2018: Cutanogen Names Richard Kagan As Chief Medical Advisor 45

Apr 05, 2018: Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor 46

Clinical Trials 47

Apr 30, 2018: Elto PharmaAppoints Paula Trzepacz, MD as Chief Medical Advisor 47

Other Significant Developments 48

Jul 20, 2018: Amarantus provides corporate update 48

May 11, 2018: Amarantus Provides Business Overview 50

Dec 01, 2017: Amarantus Provides Comprehensive Corporate Update 53

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarantus Bioscience Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13

Amarantus Therapeutics Raises USD 1.3 Million In Venture Financing 15

Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16

Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17

Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18

Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 19

Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 20

Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 21

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 23

Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 24

Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 25

Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 26

Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 27

Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 29

Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 30

Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 31

Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 33

Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 34

Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 35

Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For USD 1.6 Million 36

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 38

Amarantus Bioscience Holdings Inc, Key Competitors 39

Amarantus Bioscience Holdings Inc, Key Employees 40

Amarantus Bioscience Holdings Inc, Other Locations 41

Amarantus Bioscience Holdings Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amarantus Bioscience Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.